Dr. Todd Morgan

Whereas we know that that's fine. So I really like that less than 0.1. But there are some patients where, yeah, they're at really high risk of recurrence. And I'd like to have a sense of the trend. And yeah, if I see it's 0.06, 0.08, we know probably it's coming and we can start to lay the groundwork for potential salvage treatment.

Looks great. I think we're fine. We're keeping an eye on this.

Looks great. I think we're fine. We're keeping an eye on this.

Looks great. I think we're fine. We're keeping an eye on this.

No, I don't go there for that because it just, yeah.

No, I don't go there for that because it just, yeah.

No, I don't go there for that because it just, yeah.

Yeah, I'm worried, especially in a high-risk patient. And even, I mean, once we start getting above 0.05 with a trend, and that's a Godland statement, by the way, is if we're using ultrasensitive PSA, we need to confirm a rising ultrasensitive PSA. that we're not treating somebody because their PSA is 0.05 a couple of times in a row. Let's make sure that it's meaningful.

Yeah, I'm worried, especially in a high-risk patient. And even, I mean, once we start getting above 0.05 with a trend, and that's a Godland statement, by the way, is if we're using ultrasensitive PSA, we need to confirm a rising ultrasensitive PSA. that we're not treating somebody because their PSA is 0.05 a couple of times in a row. Let's make sure that it's meaningful.

Yeah, I'm worried, especially in a high-risk patient. And even, I mean, once we start getting above 0.05 with a trend, and that's a Godland statement, by the way, is if we're using ultrasensitive PSA, we need to confirm a rising ultrasensitive PSA. that we're not treating somebody because their PSA is 0.05 a couple of times in a row. Let's make sure that it's meaningful.

But yeah, once I see 0.1, it's notable. Again, it depends on patient's baseline risk. And so that's really an important fact to keep in mind. This is a study that we published using the CAPTURE database probably 10 years ago now, showing that your disease risk informs the meaning of a post-op PSA.

But yeah, once I see 0.1, it's notable. Again, it depends on patient's baseline risk. And so that's really an important fact to keep in mind. This is a study that we published using the CAPTURE database probably 10 years ago now, showing that your disease risk informs the meaning of a post-op PSA.

But yeah, once I see 0.1, it's notable. Again, it depends on patient's baseline risk. And so that's really an important fact to keep in mind. This is a study that we published using the CAPTURE database probably 10 years ago now, showing that your disease risk informs the meaning of a post-op PSA.

So the high-risk patient with a PSA of 0.1 is a whole lot more likely to have further progression than a low-risk patient with a PSA of 0.1. And so, you know, that's kind of intuitive, but we just exhaustively, I think, showed that using the CAPTURE database.

So the high-risk patient with a PSA of 0.1 is a whole lot more likely to have further progression than a low-risk patient with a PSA of 0.1. And so, you know, that's kind of intuitive, but we just exhaustively, I think, showed that using the CAPTURE database.

So the high-risk patient with a PSA of 0.1 is a whole lot more likely to have further progression than a low-risk patient with a PSA of 0.1. And so, you know, that's kind of intuitive, but we just exhaustively, I think, showed that using the CAPTURE database.

I think that's it. It's two things. It's one, sometimes there are some benign glands that we leave behind, right? You're right. If we have a patient who's got more favorable risk disease, especially they're young and we're doing everything possible to preserve potency, we are cutting it close. And so could we leave some glands, benign glands behind? Yeah.

I think that's it. It's two things. It's one, sometimes there are some benign glands that we leave behind, right? You're right. If we have a patient who's got more favorable risk disease, especially they're young and we're doing everything possible to preserve potency, we are cutting it close. And so could we leave some glands, benign glands behind? Yeah.

I think that's it. It's two things. It's one, sometimes there are some benign glands that we leave behind, right? You're right. If we have a patient who's got more favorable risk disease, especially they're young and we're doing everything possible to preserve potency, we are cutting it close. And so could we leave some glands, benign glands behind? Yeah.

Could we leave some lower risk prostate cancer cells behind too? Yeah. Yeah, even in margin negative patients. I mean, you've looked at those slides. Thankfully, it's a negative margin with like two cells between the cancer cell and in the margin. And so, yeah, I mean, those recurrences in that setting are lower risk. And that informs how we manage those patients, right?